RT Journal Article
SR Electronic
T1 Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP S11
OP S17
DO 10.3949/ccjm.83.s1.03
VO 83
IS 5 suppl 1
A1 Om P. Ganda
YR 2016
UL http://www.ccjm.org/content/83/5_suppl_1/S11.abstract
AB In patients with diabetes, a complex and controversial relationship exists between intensive glycemic control and cardiovascular (CV) outcomes. Although the value of glucose-lowering agents in preventing microvascular complications associated with diabetes has been established, along with reductions in ischemic coronary events, active treatment in one major glycemic-control trial resulted in an unexplained increase in CV-associated mortality and total deaths compared with controls. Questions of CV safety with specific glucose-lowering agents along with the mechanisms underlying their effects on CV events have not been fully answered, underscoring the need for additional well-designed, long-term randomized controlled trials (RCTs) to prove their CV safety vs an active comparator. The CV benefits of one sodium-glucose cotransporter-2 inhibitor reported in an RCT await confirmation in ongoing trials.